一般注記Xanthine oxidase (XO) is a rate limiting enzyme for production of uric acid. The activity of XO in plasma is reported to elevate in patients with familial hypercholesterolaemia and cardiovascular diseases. Such an increase in plasma XO activity was also demonstrated in patients with a variety of cancers. However, there have been few reports evaluating the plasma XO activity in patients with hematological malignancies during course of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and chemotherapies. We explored the relationship between plasma XO activity and clinical symptoms/biochemical parameters in 10 patients with hematological malignancies. The XO activity was measured by a highsensitivity fluorescence technique. Plasma XO activity in hematological malignancies before chemotherapy was not elevated compared to healthy subjects. In patients receiving allo-HSCT, no apparent increase in plasma XO activity was observed at the appearance of graft-versus-host disease (GVHD). Noticeably, however, the value of plasma XO activity was closely associated with that of serum level of liver transaminases in the course of allo-HSCT and chemotherapies. To our knowledge, the present study is the first to investigate consecutively the value in plasma XO activity in patients with hematological malignancies. Despite small numbers analyzed, value of plasma XO activity was tightly associated with that of serum level of liver transaminases in the course of allo-HSCT and chemotherapies, suggesting that the value may reflect liver damage related with a variety of therapeutic interventions.
学位論文
連携機関・データベース国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）